Tenax Therapeutics (TENX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 118,755 | 97,565 | 99,369 | 105,462 | 111,447 |
| Other current assets | 107 | 1,019 | 0 | 0 | 88 |
| TOTAL | $123,178 | $104,227 | $102,810 | $105,857 | $112,059 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $123,178 | $104,227 | $102,810 | $105,857 | $112,059 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,346 | 6,041 | 5,608 | 562 | 1,839 |
| Accrued Expenses | 2,140 | 1,115 | 991 | 1,965 | 929 |
| TOTAL | $8,486 | $7,156 | $6,599 | $2,527 | $2,768 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $8,486 | $7,156 | $6,599 | $2,527 | $2,768 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 26,525 | 17,198 | 6,244 | 4,563 | 4,148 |
| Common Shares | 2 | 1 | 1 | N/A | N/A |
| Retained earnings | -383,170 | -367,454 | -351,914 | -336,110 | -325,263 |
| TOTAL | $114,692 | $97,071 | $96,211 | $103,330 | $109,291 |
| Total Liabilities And Equity | $123,178 | $104,227 | $102,810 | $105,857 | $112,059 |